Combination mRNA Vaccine Adjuvanted with CpG Oligodeoxynucleotides Enhances Protection against Respiratory Virus Infection - PubMed
3 hours ago
- #mRNA vaccine
- #respiratory viruses
- #adjuvant CpG
- Combination mRNA vaccine SIR targets SARS-CoV-2, influenza, and RSV as an 8-valent vaccine.
- Adjuvant CpG-ODN 1018 added to SIR creates SIRC, enhancing immune responses.
- SIRC induces robust neutralizing antibodies and Th1-biased T-cell responses with CD4+ and CD8+ memory cells.
- In mice, SIRC protects against four influenza subtypes and RSV, showing no immune interference.
- SIRC offers superior protection compared to individual or SIR vaccines, with favorable safety and development potential.